Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in California?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. A California resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a California-licensed prescriber, including by asynchronous telehealth: Business and Professions Code section 2242 says an appropriate prior exam does not require a synchronous interaction and can be done through a questionnaire if the standard of care is met. Compounded peptides are harder to get in California than in most states, because the California State Board of Pharmacy's rewritten compounding regulations (16 CCR 1735 and 1736 series, 2025) define "essentially a copy" more strictly than federal law, and any out-of-state pharmacy shipping sterile compounded injectables into California needs both a nonresident pharmacy license and a nonresident sterile compounding license.

Regulatory: Telehealth allowedRegulatory: Async allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous allowed
Compounded GLP-1
Limited

Can a California resident get peptides by telehealth?

Business and Professions Code section 2290.5 defines telehealth to include synchronous interactions and asynchronous store and forward transfers, requires the provider to inform the patient and obtain and document verbal or written consent to telehealth, and keeps the provider subject to the same professional responsibility and practice standards that apply under the provider's license. Section 2242 makes it unprofessional conduct to prescribe a dangerous drug without an appropriate prior examination and medical indication, but states that an appropriate prior examination does not require a synchronous interaction and can be achieved through telehealth, including a self-screening tool or a questionnaire, provided the licensee complies with the appropriate standard of care. The prescriber must hold a California license; California does not offer an out-of-state telehealth registration for physicians. Peptides in this database are not controlled substances, so federal Ryan Haight limits do not apply to them. This record classifies asynchronous prescribing as allowed because section 2242(a) says in terms that the required examination need not be synchronous, and it expressly lets a self-screening tool or questionnaire serve as that examination when the standard of care is met. [6] [7] [11]

How does the California pharmacy board treat compounding?

Compounding regulator for California
BoardCalifornia State Board of Pharmacy
Eligible substancesFollows the federal 503A framework

The California State Board of Pharmacy regulates compounding under the Pharmacy Law (Business and Professions Code section 4000 and following) and Title 16 of the California Code of Regulations, sections 1735 (nonsterile) and 1736 (sterile) series, which the Board comprehensively rewrote in 2025 to align with USP chapters 795 and 797. California follows the federal 503A bulks framework for which substances may be compounded, but sets a stricter standard on copies: under 16 CCR 1735.1 and 1736.1 a compounded drug is essentially a copy of a commercially available product unless a change for an identified patient produces a clinically significant difference that the pharmacist verifies and documents, and the California rule does not treat a different strength or route alone as enough. Out-of-state pharmacies shipping into California must hold a nonresident pharmacy license under section 4112, and those shipping sterile compounded products (which includes injectable peptides) also need a nonresident sterile compounding license under section 4127.2. The Board's approved-regulations page lists the rewrite as one package (Compounded Drug Preparations: repeal and replacement of 16 CCR 1735 and following, new articles 1736, 1737, and 1738), adopted by the Board March 26, 2025, approved by the Office of Administrative Law June 19, 2025, and effective October 1, 2025; the page shows no separate earlier effective date for the essentially-a-copy provisions. [1] [2] [3] [4] [5] [8] [9] [12]

Can you get compounded GLP-1s in California?

Regulatory: Compounded GLP-1 limited

Branded Wegovy, Zepbound, Ozempic, and Mounjaro are available from California pharmacies, and California's telehealth law lets a California-licensed prescriber issue a branded prescription after an asynchronous exam if the standard of care is met and telehealth consent is documented. Compounded semaglutide and tirzepatide are more restricted in California than federal law alone requires: beyond the end of the FDA shortage allowances in 2025, California pharmacists must document a clinically significant difference for the individual patient before compounding a GLP-1 that matches a commercial product, and a lower price is not a qualifying reason. The Board's rules allow shortage-based compounding again only if the drug returns to the FDA or ASHP shortage list. [3] [6] [7] [15]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in California?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in California

What you'll actually find in California, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [19] [20] [21]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [22]

What California has done

PeptideAgent has not found a board or legislative action on peptides in California.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in California. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law lets a prescriber rely on a reviewed online questionnaire. [6] [7] [11] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the California State Board of Pharmacy; its license search: FDA BeSafeRx: state board of pharmacy license lookups. [23]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [22]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [13] [27] [28]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [29] [30]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [21] [30] [31]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [22] [32] [33] [34] [35] [36]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [22]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [21]
  • Pharmacy: Is this made for me on a prescription written in my name? [31]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [21] [30]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [21]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in California?

California's Sherman Food, Drug, and Cosmetic Law bars selling, delivering, or giving away any new drug in California unless it has federal approval or a California approval (Health and Safety Code section 111550). "Research use only" peptides sold for human use are unapproved new drugs under both the Sherman Law and federal law, and only licensed pharmacies may dispense prescription drugs to California patients. [10] [16]

Peptide-specific notes for California

Peptide-specific notes for California
PeptideNote
SemaglutideAvailable branded by prescription from a California-licensed prescriber, including after an asynchronous telehealth exam such as a questionnaire under Business and Professions Code section 2242, if the prescriber meets the appropriate standard of care. Compounded semaglutide requires a documented clinically significant difference for the patient under California's 2025 essentially-a-copy rules, a stricter bar than the federal patient-specific exception. [3] [7] [15]
TirzepatideAvailable branded by prescription. Compounded tirzepatide faces the same California clinically significant difference requirement, and any compounded vial shipped from outside California must come from a pharmacy holding a nonresident sterile compounding license under section 4127.2. [3] [9]
BPC-157Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). California pharmacies apply the federal bulks test plus the Board's rewritten compounding standards, and the Board has not issued a BPC-157 specific rule. [2] [13] [14] [17] [18]

Compare: Wegovy vs Zepbound.

Frequently asked questions

Can I get a GLP-1 prescription in California through an online questionnaire?

Yes, if the prescriber meets the standard of care. California Business and Professions Code section 2242 says an appropriate prior exam does not require a synchronous interaction and can be done through telehealth, including a self-screening tool or questionnaire. The prescriber must be California-licensed and must document your consent to telehealth under section 2290.5. [6] [7]

Why is compounded semaglutide harder to get in California than in other states?

California's 2025 compounding regulations treat a compounded drug as essentially a copy of a commercial product unless a change made for you produces a clinically significant difference that the pharmacist verifies and documents. That is stricter than the federal standard, and price is not a valid reason. [3] [15]

What licenses does an out-of-state pharmacy need to ship injectable peptides to California?

Two. It needs a nonresident pharmacy license under Business and Professions Code section 4112, and because injectable peptides are sterile compounded products it also needs a nonresident sterile compounding license under section 4127.2. Verify both on the Board of Pharmacy license lookup. [1] [8] [9]

Can a California pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: California follows the federal 503A bulks framework plus the Board's rewritten compounding standards, and the Board has not issued a BPC-157 specific rule. [2] [13] [14] [17] [18]

Is it legal to buy research peptides online in California?

Not for human use. Health and Safety Code section 111550 bars selling or delivering an unapproved new drug in California, and research-labeled peptides sold for injection are unapproved new drugs under both state and federal law. [10] [16]

From the blog

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]California State Board of Pharmacy
  2. [2]California State Board of Pharmacy: laws and regulations (Pharmacy Law and 16 CCR compounding sections)
  3. [3]California Board of Pharmacy: regulation text, compounding in licensed pharmacies (16 CCR 1735 and following, including the essentially-a-copy definition)
  4. [4]California State Board of Pharmacy: approved regulations (Compounded Drug Preparations, effective October 1, 2025; OAL approval June 19, 2025), accessed 2026-09-22
  5. [5]California State Board of Pharmacy: compounding policy statement (June 19, 2025 notice of approval, regulations effective October 1, 2025), accessed 2026-09-22
  6. [6]California Business and Professions Code section 2290.5, Telehealth (as amended by Stats. 2025, Ch. 413, effective January 1, 2026), accessed 2026-09-30
  7. [7]California Business and Professions Code section 2242, Prescribing without an appropriate prior examination
  8. [8]California Business and Professions Code section 4112, Nonresident pharmacy license
  9. [9]California Business and Professions Code section 4127.2, Nonresident sterile compounding pharmacy license
  10. [10]California Health and Safety Code section 111550, New drugs (Sherman Food, Drug, and Cosmetic Law)

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in California?. https://peptideagent.ai/legal/california
HTML link
<a href="https://peptideagent.ai/legal/california">Are peptides legal in California?</a>, PeptideAgent, updated October 28, 2026.